Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

RETRACTED ARTICLE: Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease

Authors: Barbara Nuvoli, Sabrina Germoni, Carlotta Morosetti, Raffaela Santoro, Giancarlo Cortese, Serena Masi, Iole Cordone, Rossella Galati

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of mesothelioma using in vitro and in vivo preclinical models.

Results

We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/exemestane is more effective than pemetrexed/cisplatin.

Conclusion

The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma treatment.
Appendix
Available only for authorised users
Literature
1.
Robinson LA, Reilly RB: Localized pleural mesothelioma. The clinical spectrum. Chest. 1994, 106: 1611-1615. 10.1378/chest.106.5.1611CrossRef
2.
Broaddus VC: Asbestos, the mesothelial cell and malignancy: a matter of life or death. Am J Respir Cell Mol Biol. 1997, 17: 657-659. 10.1165/ajrcmb.17.6.f141CrossRef
3.
Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y: Asbestos-related lung cancer and mesothelioma in Japan. Ind Health. 2001, 39: 65-74. 10.2486/indhealth.39.65CrossRef
4.
Dufresne A, Bégin R, Churg A, Massé S: Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec. Am J Respir Crit Care Med. 1996, 153: 711-718. 10.1164/ajrccm.153.2.8564122CrossRef
5.
Pass HI, Bocchetta M, Carbone M: Evidence of an important role for SV40 in mesothelioma. Thorac Surg Clin. 2004, 14: 489-495. 10.1016/j.thorsurg.2004.06.003CrossRef
6.
Bianchi C, Bianchi T: Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007, 45: 379-387. 10.2486/indhealth.45.379CrossRef
7.
Robinson BM: Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012, 1: 491-496.
8.
Sugarbaker DJ, Norberto JJ: Multimodality management of malignant pleural mesothelioma. Chest. 1998, 113: 61S-65S. 10.1378/chest.113.1_Supplement.61SCrossRef
9.
Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, Kucukoner M, Kaplan MA, Celik Y, Senyigit A: Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci. 2013, 17: 19-24.
10.
Nowak AK: Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg. 2012, 1: 508-515.
11.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003, 15: 2636-2644.CrossRef
12.
Cartron PF, Blanquart C, Hervouet E, Gregoire M, Vallette FM: HDAC1-mSin3a-NCOR1, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a regulate the NY-ESO1 gene expression. Mol Onco. 2013, 7: 452-463. 10.1016/j.molonc.2012.11.004.CrossRef
13.
Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, Weder W, Stahel RA, Felley-Bosco E: Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res. 2012, 18: 4646-4656. 10.1158/1078-0432.CCR-12-0599CrossRef
14.
Zhang Y, He J, Zhang F, Li H, Yue D, Wang C, Jablons DM, He B, Lui N: SMO expression level correlates with overall survival in patients with malignant pleural mesothelioma. J Exp Clin Cancer Res. 2013, 32: 7- 10.1186/1756-9966-32-7CrossRef
15.
Heintz NH, Janssen-Heininger YM, Mossman BT: Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol. 2010, 42: 133-139. 10.1165/rcmb.2009-0206TRCrossRef
16.
Jablons DM, Eguchi K: Targeting the Wnt signaling pathway with dishevelled and cisplatin synergistically suppresses mesothelioma cell growth. Anticancer Res. 2007, 27: 4239-4242.
17.
Stoppoloni D, Salvatori L, Biroccio A, D’Angelo C, Muti P, Verdina A, Sacchi A, Vincenzi B, Baldi A, Galati R: Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. J Thorac Oncol. 2011, 6: 583-591. 10.1097/JTO.0b013e31820cdd6fCrossRef
18.
Nuvoli B, Galati R: Cyclooxygenase-2, epidermal growth factor receptor and aromatase signalling in inflammation and mesothelioma. Mol Cancer Ther. 2013, 12: 1-9. 10.1186/1476-4598-12-1.CrossRef
19.
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E: Histological typing of lung and pleural tumors. World Health Organization international histological classification of tumors. Edited by: Springer-Verlag. 1999, Berlin: Springer-Verlag, 3
20.
Tudor EC, Chua TC, Liauw W, Morris DL: Risk factors and clinicopathological study of prognostic factors in thè peritoneal mesothelioma. Am Surg. 2010, 76: 400-405.CrossRef
21.
Pillai K, Pourgholami MH, Chua TC, Morris DL: Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 2013, 139: 987-994. 10.1007/s00432-013-1408-2CrossRef
22.
Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, Levine EA: Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004, 17: 476-481. 10.1038/modpathol.3800067CrossRef
23.
Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009, 69: 4598-4604. 10.1158/0008-5472.CAN-08-4523CrossRef
24.
Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H: Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer. 2009, 8: 109- 10.1186/1476-4598-8-109CrossRef
25.
Ramos-Nino ME, Blumen SR, Pass H, Mossman BT: Fra-1 governs cell migration via modulation of CD44 expression in human mesotheliomas. Mol Cancer. 2007, 6: 81- 10.1186/1476-4598-6-81CrossRef
26.
Miller WR: Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer. 1999, 6: 187-195. 10.1677/erc.0.0060187CrossRef
27.
Brueggemeier RW: Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat. 2002, 74: 177-185. 10.1023/A:1016121822916CrossRef
28.
Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM: An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002, 95: 2006-2016. 10.1002/cncr.10908CrossRef
29.
Deeks ED, Scott LJ: Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs. 2009, 69: 889-918. 10.2165/00003495-200969070-00007CrossRef
30.
Chen S, Zhou D, Yang C, Okubo T, Kinoshita Y, Yu B, Kao YC, Itoh T: Modulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol. 2001, 79: 35-40. 10.1016/S0960-0760(01)00132-7CrossRef
31.
Hagiwara M, Brindle P, Harootunian A, Armstrong R, Rivier J, Vale W, Tsien R, Montminy MR: Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol. 1993, 8: 4852-4859.
32.
Taylor SS, Buechler JA, Yonemoto W: cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem. 1990, 59: 971-1005. 10.1146/annurev.bi.59.070190.004543CrossRef
33.
Kopperud R, Christensen AE, Kjarland E, Viste K, Kleivdal H, Døskeland SO: Formation of inactive cAMP-saturated holoenzyme of cAMP-dependent protein kinase under physiological conditions. J Biol Chem. 2002, 277: 13443-13448. 10.1074/jbc.M109869200CrossRef
34.
Smith CM, Radzio-Andzelm E, Madhusudan Akamine P, Taylor SS: The catalytic subunit of cAMP-dependent protein kinase: prototype for an extended network of communication. Prog Biophys Mol Biol. 1999, 71: 313-341. 10.1016/S0079-6107(98)00059-5CrossRef
35.
Harootunian AT, Adams SR, Wen W, Meinkoth JL, Taylor SS, Tsien RY: Movement of the free catalytic subunit of cAMP-dependent protein kinase into and out of the nucleus can be explained by diffusion. Mol Biol Cell. 1993, 4: 993-1002. 10.1091/mbc.4.10.993CrossRef
36.
Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, Nagata Y, Nakagawa M, Uramoto H, So T, Tanaka F: Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012, 33: 2135-2141. 10.1007/s13277-012-0473-5CrossRef
37.
Sneath RJ, Mangham DC: The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 1998, 51: 191-200. 10.1136/mp.51.4.191CrossRef
38.
Bates RC, Edwards NS, Burns GF, Fisher DE: A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001, 61: 5275-5283.
39.
Waiters J, Campbell JS, Cunningham MJ, Krebs EG, Dorsa DM: Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology. 1997, 138: 4030-4033. 10.1210/endo.138.9.5489CrossRef
40.
Simoncini T, Rabkin E, Liao JK: Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol. 2003, 23: 198-203. 10.1161/01.ATV.0000053846.71621.93CrossRef
41.
Kelly MJ, Wagner EJ: Estrogen modulation of G-protein-coupled receptors. Trends Endocrinol Metab. 1999, 10: 369-374. 10.1016/S1043-2760(99)00190-3CrossRef
42.
Filardo EJ, Quinn JA, Frackelton AR, Bland KI: Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002, 16: 70-84. 10.1210/mend.16.1.0758CrossRef
43.
Spugnini EP, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A: Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res. 2006, 12: 6133-6143. 10.1158/1078-0432.CCR-06-1056CrossRef
44.
Canino C, Mori F, Cambria A, Diamantini A, Germoni S, Alessandrini G, Borsellino G, Galati R, Battistini L, Blandino R, Facciolo F, Citro G, Strano S, Muti P, Blandino G, Cioce M: SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. Oncogen. 2012, 31: 3148-3163. 10.1038/onc.2011.485.CrossRef
45.
Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R: Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005, 11: 982-992.CrossRef
46.
Hazarika M, White RM, Johnson JR, Pazdur R: FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004, 9: 482-488. 10.1634/theoncologist.9-5-482CrossRef
47.
Varela C, Tavares da Silva EJ, Amaral C, Correia da Silva G, Baptista T, Alcaro S, Costa G, Carvalho RA, Teixeira NA, Roleira FM: New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation. J Med Chem. 2012, 55: 3992-4002. 10.1021/jm300262wCrossRef
48.
Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European organisation for research and treatment of cancer breast cancer cooperative group. J Clin Oncol. 2008, 26: 4883-4890. 10.1200/JCO.2007.14.4659CrossRef
49.
Liu H, Talalay P: Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc Natl Acad Sci USA. 2013, 110: 19065-19070. 10.1073/pnas.1318247110CrossRef
50.
Stoppoloni D, Cardillo I, Verdina A, Vincenzi B, Menegozzo S, Santini M, Sacchi A, Baldi A, Galati R: Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer. 2008, 113: 2761-2769. 10.1002/cncr.23904CrossRef
51.
Stoppoloni D, Canino C, Cardillo I, Verdina A, Baldi A, Sacchi A, Galati R: Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010, 9: 27- 10.1186/1476-4598-9-27CrossRef
Metadata
Title
RETRACTED ARTICLE: Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease
Authors
Barbara Nuvoli
Sabrina Germoni
Carlotta Morosetti
Raffaela Santoro
Giancarlo Cortese
Serena Masi
Iole Cordone
Rossella Galati
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-69

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3ζ

Research

miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25

Research

The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases

Research

Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the AKT/FOXO3a signaling pathway

Research

Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma

Research

Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits